DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

Pityrosporum ovale, 1830
Pivoxicam, 990
PKA, 56
PKG, 56
Placebo, effectiveness determination
and choice of, 9
Placental lactogen (PL), 1106t
Placental transfer of drugs, 25
PLAN B (levonorgestrel), 1836t, 1837
PLAQUENIL (hydroxychloroquine),
1792, 1819
Plasma binding
alteration for individual patients,
1806
of common drugs, 1809t–1890t
distribution and, 24
as pharmacodynamic parameter,
1803
Plasma clearance, as
pharmacodynamic
parameter, 1803–1804
Plasma osmolality
and hypovolemia/hypotension, 704,
704f
and plasma levels of vasopressin,
703, 703f
Plasma proteins, distribution of drugs
and, 24
Plasmin, 852
Plasminogen, 852
Plasminogen activator inhibitor 1
(PAI-1), 852
Plasminogen activator inhibitor 2
(PAI-2), 852
Plasminogen activators, 852
Plasticity, nervous system, 366
Platelet(s)
activation, 849
adhesion, 849, 850f
aggregation, 849, 850f
eicosanoids and, 946, 949
platelet-activating factor and, 954
serotonin and, 340
Platelet-activating factor (PAF), 937,
952–955
and allergic response, 954
biosynthesis of, 952–953, 953f
cardiovascular effects of, 954
chemistry of, 952–953
degradation of, 953f
gastric effects of, 955
histamine and, 914
history of, 952
inactivation of, 953
and inflammation, 954
in inflammation, 960
Platelet-activating factor (PAF)
(Cont.):
and leukocytes, 954
mechanism of action of, 953
pharmacology of, 953–955
physiological and pathological
functions of, 954–955
and platelets, 954
receptor antagonists, 955
renal effects of, 955
and reproduction/parturition, 954
and smooth muscle, 954
structure of, 952
Platelet-derived growth factor (PDGF),
1738
Platelet factor 4, 855
Platelets, alpha adrenergic receptors in,
203t
Platinum coordination complexes
chemistry of, 1688
cytotoxic actions of, 1680–1681
mechanism of action of, 1688
for neoplastic disease, 1668t–1670t
pharmacological actions of,
1680–1681
resistance to, 1688
structure-activity relationships,
1678–1680
PLC. See Phospholipase C (PLC)
PLENDIL (felodipine), 762t
PML. See Progressive multifocal
leukoencephalopathy (PML)
Pneumocystis jiroveci, 1469–1470
Pneumonia, pneumococcal, penicillin
D for, 1485
PNMT. See Phenylethanolamine-Nmethyltransferase
(PNMT)
Podophyllin/podofilox
adverse effects and side effects of,
1830
for anogenital warts, 1830
for cutaneous viral infections, 1818
dosage and administration of, 1830
mechanism of action of, 1830
Podophyllum resin. See
Podophyllin/podofilox
Poison, definition of, 73
Poisoning
absorption and, 75
anticholinesterase, 234
in children, 80
clinical toxicity pattern
identification in, 82
decontamination of patient in, 82–85
differential diagnosis in,
electrocardiographic, 83t
Poisoning (Cont.):
elimination and, 75
epidemiology of, 79–80
home prevention of, 81–82
with H 1
receptor antagonists, 923
intentional, 80
most-frequent substances in, 80t
mushroom, 225
prevention of, 80–82
resources, 85–86
scenarios for, 79t
stabilization of patient in, 82
treatment principles, 82–85
Poison ivy, H 1
receptor antagonists for,
922
Polyarteritis nodosa,
cyclophosphamide for, 1821
Polycystic ovary syndrome (PCOS)
effects on ovulation and fertility,
1845
and hirsutism, 1840
insulin sensitizers for, 1845
and obesity, 1841
Polycythemia vera, drugs for, 1668t–
1670t
Polyenes, for ophthalmic use, 1784t
Polyethylene glycol electrolyte
solution, 84–85, 1332–1333
Polyhexamethylene biguanide, for
ophthalmic use, 1784
POLY-HISTINE-D (pyrilamine maleate),
921t
Polymers, biocompatible, 23
Polymorphism, 147, 147f, 148
causative, 153
cosmopolitan, 150
disease and, 151
ethnic diversity and, 150
functional studies of, 153–156
intergenic, 155t
intron/exon, 155t
intron/exon boundary, 155t
intronic, 155t
nonsense, 155t
nonsynonymous, 155t
population specific, 150
regulatory region, 155t
selection, 151
synonymous, 148, 155t
target, 162–163
Polymorphous light eruption,
antimalarials for, 1819
Polymyxin B
histamine and, 914
prophylaxis, for superficial
infections, 1817
2061
INDEX